Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 9.95% is 119% above its 5-year average of -52.46%, near the high end of its 5-year range (-111.33%–9.95%).
As of the fiscal period ended Tuesday, June 30, 2026. 219.94% above its 12-month average of -8.29%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 9.95%.
RETURN ON INVESTED CAPITAL (ROIC)
9.95%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-8.29%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-38.27%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-52.46%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+219.94%
CURRENT VS 3Y AVG
+126.00%
CURRENT VS 5Y AVG
+118.96%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.19%
median of 714 covered companies
CURRENT VS SECTOR MEDIAN
+129.98%
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$3.07B
Return on Invested Capital (ROIC)
9.95%
TTM Avg
-8.29%
3Y Avg
-38.27%
5Y Avg
-52.46%
Market Cap
$3.07B
Return on Invested Capital (ROIC)
-66.60%
TTM Avg
-119.97%
3Y Avg
-72.56%
5Y Avg
-159.91%
Market Cap
$3.07B
Return on Invested Capital (ROIC)
-13.88%
TTM Avg
-29.89%
3Y Avg
-36.62%
5Y Avg
-30.08%
Market Cap
$3.14B
Return on Invested Capital (ROIC)
-50.82%
TTM Avg
-45.69%
3Y Avg
-35.19%
5Y Avg
-27.59%
Market Cap
$2.88B
Return on Invested Capital (ROIC)
-58.28%
TTM Avg
-46.81%
3Y Avg
-91.88%
5Y Avg
-70.41%
Market Cap
$2.81B
Return on Invested Capital (ROIC)
5.87%
TTM Avg
7.96%
3Y Avg
-0.22%
5Y Avg
-9.17%
Market Cap
$2.80B
Return on Invested Capital (ROIC)
2.04%
TTM Avg
-4.01%
3Y Avg
-5.25%
5Y Avg
-2.96%
Market Cap
$3.34B
Return on Invested Capital (ROIC)
-409.85%
TTM Avg
-257.76%
3Y Avg
-257.76%
5Y Avg
-257.76%
Market Cap
$3.41B
Return on Invested Capital (ROIC)
-0.93%
TTM Avg
1.17%
3Y Avg
-16.63%
5Y Avg
-13.35%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.07B | 9.95% | -8.29% | -38.27% | -52.46% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.07B | -66.60% | -119.97% | -72.56% | -159.91% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.07B | -13.88% | -29.89% | -36.62% | -30.08% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.14B | -50.82% | -45.69% | -35.19% | -27.59% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -58.28% | -46.81% | -91.88% | -70.41% |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | 5.87% | 7.96% | -0.22% | -9.17% |
| AtriCure, Inc. (ATRC)vs › | $2.80B | 2.04% | -4.01% | -5.25% | -2.96% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | -409.85% | -257.76% | -257.76% | -257.76% |
| CareDx, Inc (CDNA)vs › | $3.41B | -0.93% | 1.17% | -16.63% | -13.35% |
| Precigen, Inc. (PGEN)vs › | $2.72B | -28.02% | -99.23% | -79.58% | -63.04% |
ROIC
9.9%
ROE
12.9%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | 9.95% |
| 2026-03-31 | 1.05% |
| 2025-12-31 | -4.02% |
| 2025-09-30 | -14.05% |
| 2025-06-30 | -34.40% |
| 2025-03-31 | -47.95% |
| 2024-12-31 | -47.93% |
| 2024-09-30 | -49.92% |
| 2024-06-30 | -45.70% |
| 2024-03-31 | -45.48% |
| 2023-12-31 | -81.81% |
| 2023-09-30 | -98.92% |
| 2023-06-30 | -111.33% |
| 2023-03-31 | -92.07% |
| 2022-12-31 | -73.31% |
| 2022-09-30 | -64.54% |
| 2022-06-30 | -94.08% |
| 2022-03-31 | -70.28% |
| 2021-12-31 | -55.04% |
| 2021-09-30 | -45.98% |
| 2021-06-30 | -35.87% |
| 2021-03-31 | -31.59% |
| 2020-12-31 | -49.57% |
| 2020-09-30 | -65.35% |
| 2020-06-30 | -43.20% |
| 2020-03-31 | -26.75% |
| 2019-12-31 | -42.38% |
| 2019-09-30 | -183.17% |
| 2019-06-30 | -85.68% |
| 2018-12-31 | -40.75% |
